Drug intelligence / Profile preview

KDSTEM inj.

Development stage: Phase 1
Lead developer: EHL Bio
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

KDSTEM inj. is an autologous cell therapy product composed of urine-derived stem cells (USCs) developed by EHL Bio for the treatment of chronic kidney disease (CKD). USCs are a unique population of progenitor cells that can be isolated non-invasively from human urine and possess mesenchymal stem cell (MSC)-like characteristics, including multi-lineage differentiation potential and potent paracrine activity. In the context of CKD, KDSTEM inj. is intended to facilitate renal tissue repair and modulate inflammatory processes through the secretion of growth factors and cytokines. The therapy is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and preliminary efficacy in patients with impaired kidney function.

Other names: autologous urine-derived stem cells

Beyond the preview

Go deeper on KDSTEM inj..

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KDSTEM inj..

Explore the full profile